Final Day! Goldline Pharmaceutical IPO Crosses 100x Subscription; GMP Soars Over 50%

Goldline Pharmaceutical IPO, which opened for subscription on Tuesday, May 12, will close today (May 14). The shares are set to debut on the BSE SME platform, with the tentative listing date scheduled for May 19. The share allotment is expected to be finalised on May 15.

Here's a look at the Goldline Pharmaceutical IPO details including the live subscription status, the latest GMP, and other important details investors should know as bidding enters its final day.

Goldline Pharmaceutical IPO Day 3 Subscription Status Live

According to BSE, the Goldline Pharmaceutical IPO was subscribed 126.70 times as of 10:07 am on Thursday. The issue received bids for 24,93,54,000 shares against the 19,68,000 shares on offer.

Retail investors drove the demand, subscribing to their portion 178.06 times. The Non-Institutional Investor (NII) category was booked 167.37 times, while the Qualified Institutional Buyers (QIB) segment saw a subscription of 1.35 times.

Goldline Pharmaceutical IPO Latest GMP

According to InvestorGain, Goldline Pharmaceutical SME IPO's latest GMP stands at Rs 25 on May 14. Based on the upper end of the price band of Rs 43, the estimated listing price stands at Rs 68 per share, implying a potential gain of 58.14% on listing.

Goldline Pharmaceutical IPO Details

Goldline Pharmaceutical IPO is a book-built issue of Rs 11.61 crore. The IPO consists entirely of a fresh issue of 27 lakh shares. The price band was fixed between Rs 41 and Rs 43 per share. The minimum lot size for retail investors is 3,000 shares. Retail investors must apply for at least two lots, or 6,000 shares, taking the minimum investment amount to Rs 2.58 lakh. For HNI investors, the minimum application size is three lots, or 9,000 shares, amounting to Rs 3.87 lakh.

Cumulative Capital Pvt. Ltd. is the book-running lead manager for the issue, while Bigshare Services Pvt. Ltd. is the registrar. Nirman Share Brokers Pvt. Ltd. is the market maker for the IPO.

About Goldline Pharmaceutical

Goldline Pharmaceutical operates across multiple therapeutic segments. The company's portfolio is divided into five segments. Goldline Pharma has 42 products focused on specialities such as orthopaedics, ENT, gastroenterology, neurology, urology and surgery.

Goldline Cardinal offers 54 products for physicians, diabetologists, endocrinologists and cardiologists. Goldline Aayushman includes 18 products catering to paediatricians, neonatologists and child specialists. Goldline InLife has 22 products aimed at intensivists, critical care consultants and super-speciality surgeons. Goldline Wellness includes 10 products focused on supportive care in cancer treatment.